Novakand Pharma AB
3EE0
Company Profile
Business description
Novakand Pharma AB is developing a new class of innovative drugs focusing on inflammatory diseases and cancer. The company is developing a new class of small molecule drugs that control disease promoting immune cells with precision, by targeting the fractalkine axis.
Contact
Nanna Svarts vag 4
Solna171 65
SWET: +46 850126080
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
5
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,874.20 | 25.80 | 0.29% |
| CAC 40 | 8,095.58 | 10.58 | -0.13% |
| DAX 40 | 24,074.25 | 2.62 | -0.01% |
| Dow JONES (US) | 48,262.16 | 147.90 | 0.31% |
| FTSE 100 | 9,838.60 | 153.81 | 1.59% |
| HKSE | 25,468.78 | 233.37 | 0.92% |
| NASDAQ | 23,079.47 | 32.00 | -0.14% |
| Nikkei 225 | 49,512.28 | 128.99 | 0.26% |
| NZX 50 Index | 13,295.91 | 129.04 | -0.96% |
| S&P 500 | 6,798.20 | 2.06 | -0.03% |
| S&P/ASX 200 | 8,585.20 | 21.60 | 0.25% |
| SSE Composite Index | 3,870.28 | 45.47 | 1.19% |